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Abstract: Nonsteroidal anti-inflammatory drugs (NSAIDs), including naproxen and 
naproxen sodium, are effective yet nonspecific analgesic and anti-inflammatory drugs, 
which work for a variety of pain and inflammatory syndromes, including migraine. In 
migraine, their analgesic effect helps relieve the headache, while their anti-inflammatory 
effect decreases the neurogenic inflammation in the trigeminal ganglion. This is the hypoth-
esized mechanism by which they prevent the development of central sensitization. Triptans, 
including sumatriptan, work early in the migraine process at the trigeminovascular unit as 
agonists of the serotonin receptors (5-HT receptors) 1B and 1D. They block vasoconstric-
tion and block transmission of signals to the trigeminal nucleus and thus prevent peripheral 
sensitization. Therefore, combining these two drugs is an attractive modality for the abor-
tive treatment of migraine. Sumatriptan–naproxen fixed combination tablet (Treximet® 
[sumatriptan–naproxen]) proves to be an effective and well tolerated drug that combines 
these two mechanisms; yet is far from being the ultimate in migraine abortive therapy, and 
further research remains essential.
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Introduction to management of acute migraine
The lifetime prevalence of headache is over 90%.1 Tension type headache is the most 
common of the primary headache disorders, with a prevalence of 42% to 78%.1,2 
Migraines on the other hand occur at a frequency of 18% to 33% in females vs 
7% to 13% males.3,4 It is estimated however that over half of migraineurs remain 
undiagnosed!5
The burden of migraine is not negligible. Around a quarter of migraineurs lose 
6 or more days of work per year,6 resulting in $300 to $570 per month of lost labor per 
patient7 and over $1,600 per year in individual medical cost.8 This amounts to a total 
societal cost of $5 to $17 billion per year.7 In a more recent large population-based 
study, 2/3 of migraineurs experienced one or more attacks every month.9 Nonetheless, 
until recently, research in migraine management has lagged behind other fields of 
medicine.
In formulating a treatment strategy for migraine, it is recommended that the approach 
be multidimensional, including:10 a) Nonpharmacologic approaches and physical 
techniques, such as behavioral medicine techniques, manipulation, acupuncture, and 
physical therapy; b) Abortive therapy; c) Prophylactic therapy; d) Adjunctive therapies 
in migraine (vitamins, minerals, supplements, herbs), eg, vitamin B-2, Mg, feverfew, 
petasites, melatonin, coenzyme Q10.Drug Design, Development and Therapy 2010:4 10
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A recent guideline published by the European Federation 
of Neurologic Societies (EFNS)11 lists the following symp-
tomatic treatments for individual headache attacks or abor-
tive therapy (organized between specific and nonspecific 
treatments):
a)  nonspecific therapy with medications that relieve pain, 
including: i) NSAIDs: aspirin, ibuprofen, naproxen, 
diclofenac, paracetamol, other NSAIDs and NSAIDs 
combined with nonNSAID analgesics, ii) nonnarcotic 
pain medication: caffeine, tramadol; iii) narcotics, 
noting that these are only of minor efficacy; iv) anti-
emetics: metoclopramide, domperidon; v) cortico-
steroids; vi) intravenous valproate; vii) semi-specific 
medications: isomethoptene, butalbital (not in the EFNS 
guideline).
b)  specific abortive medications: i) triptans, ii) ergot deriva-
tives: ergotamine, dihydroergotamine (DHE).
Prophylactic anti-migraine therapy (PAMT) includes 
a multitude of agents with varying degrees of data to 
support them: a) agents with a level A recommendation: 
i) certain beta-adrenergic blockers (metoprolol, propranolol); 
ii) flunarizine, certain anticonvulsants (topiramate, val-
proate). b) agents with less supportive data: i) tricyclic 
antidepressants, especially amitriptyline; ii) NSAIDs 
(naproxen, aspirin); iii) petasites; iv) other beta-
adrenergic blockers (bisoprolol); v) other anticonvulsants 
(gabapentin), neutraceuticals: magnesium, feverfew 
(Tenacetum parthenium), riboflavin, coenzyme Q10, vi) 
angiotensin converting enzyme (ACE) inhibitors (lisino-
pril) and angiotensin-receptor blockers (ARB) (candasar-
tan), vii) methysergide, viii) calcium-channel blockers 
other than flunarizine, ix) other antidepressants, especially 
serotonin-norepinephrine reuptake inhibitors (SNRI) (such 
as venlafaxine), x) botulinum toxin A, possibly in chronic 
migraineurs naïve to other prophylactic treatments.
A holistic approach is therefore advantageous, as the 
combination of different treatments may be synergistic, 
especially if combining therapeutic categories. This also 
allows the addressing of migraine comorbidities.
The role of prophylaxis is to decrease the burden of 
headache by decreasing the frequency and severity of the 
headache. Prophylaxis may also enhance the efficacy of 
abortive therapies. In choosing a prophylactic medication, 
one should assess the burden of disability from migraine, 
assess triggers (sleep, diet, or hormones), set reasonable 
expectations, and respect patient tolerance in terms of 
speed of action of the medicine versus the tolerance of side 
effects.
There are no clear guidelines for recommending 
prophylactic treatment. This is a multidimensional assess-
ment, and considerations include: a) More than 2 attacks a 
month; b) Inadequate relief from or contraindication to abor-
tive treatment; c) Prolonged, poorly responsive menstrual 
migraine; d) Degree of disability due to migraine.
Once prophylactic medications are started, the treating 
physician should monitor the patient for side effects, and 
reassess efficacy, keeping in mind that it often takes more 
than 6 weeks for efficacy to be perceived.
Abortive therapy should be individually tailored, taking 
into consideration the medication class, route of administra-
tion, dosing, contraindications, development of tachyphylaxis, 
and side effects. Effectiveness may vary from subject to 
subject. Maximum tolerated doses should be tried before 
concluding a drug is ineffective. Often abortive treatments 
may need to be varied over time, as some patients appear to 
develop tachyphylaxis.
Overview of mode of action 
of sumatriptan–naproxen
Since migraine has multiple pathogenic mechanisms at play, 
using combination therapy is an attractive modality. The 
combination tablet contains 85 mg sumatriptan and 500 mg 
naproxen.12
Naproxen is a NSAID that is available in the US 
either as a propionic acid (naproxen) or its sodium salt 
(naproxen sodium). 200 mg naproxen base is equivalent 
to 220 mg naproxen sodium.13,14 It possesses analgesic, 
anti-inflammatory and antipyretic properties by decreasing 
the formation of prostaglandin precursors. This is mediated 
through reversible inhibition of the cyclooxygenase-1 and 2 
(COX-1 and 2) enzymes. Its desired effects are thought 
to be mediated through the inhibition of COX-2 while its 
undesirable side effects are mediated through inhibition 
of COX-1.15–20 It is labeled for use in the management of 
arthritis (ankylosing spondylitis, osteoarthritis, rheumatoid 
disorders, and gout), mild-to-moderate pain, tendonitis, 
bursitis, dysmenorrhea, fever, and for the management 
of dental pain and swelling.13,21–26 The use of naproxen in 
migraine is based on its recommended use for the treat-
ment of mild to moderate pain. It is therefore a nonspecific 
symptomatic treatment in migraine which remains an unla-
beled use in the United States. The recommended initial 
dosing in migraine therapy is 500–750 mg, with additional 
doses of 250–500 mg given as needed up to a maximum 
daily dose of 1250 mg. Enteric-coated formulations of 
naproxen are not recommended for the treatment of acute Drug Design, Development and Therapy 2010:4 11
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migraine attacks.27–29 Naproxen and naproxen-sodium 
have been tested for migraine prophylaxis with modest 
results.30
Sumatriptan was the first approved antimigraine agent 
in the United States by the Food and Drug administra-
tion (FDA) in 1991. It was initially thought to act as an 
agonist at the 5-HT1B receptor causing vasoconstriction 
and pain relief. However, no temporal correlation was 
identified between the vasoconstriction and pain relief, so 
other receptors were sought. These were shown to be the 
5-HT1D receptors, which are densely localized in humans 
on tissues known to be involved in the pathogenesis of 
migraine, such as the carotid artery, the circle of Willis, 
and meninges. They co-localize to nerve endings that also 
show immunoreactivity to the calcitonin gene related pep-
tide (CGRP) and tyrosine hydroxylase, implicating them 
in the inhibition of neurogenic inflammation.31 Therefore, 
triptans are now known to be selective 5-HT1B,1D receptor 
agonists. Both the 5-HT1B and 5-HT1D receptors belong 
to the 5-HT1D receptor subfamily and are expressed in 
the trigeminal ganglion, substantia nigra and basal gan-
glia, where triptans exert their central effect, regulating 
the firing rate of dopaminergic neurons. Peripherally, 
5-HT1B receptor is expressed on cranial blood vessels 
and mediates vasoconstriction while the 5-HT1D receptor 
is expressed on trigeminal nerve endings. There, it func-
tions as an autoreceptor, inhibiting serotonin release and 
decreasing neurogenic inflammation.32
Triptans are preferred to ergotamine and ergotamine 
derivatives, because they are at least as potent, with better 
tolerability and fewer side effects. While triptans are direct 
agonists at the 5-HT1B,1D receptors, ergotamine has nonspe-
cific partial activity at the tryptaminergic, dopaminergic, and 
alpha-adrenergic receptors. This leads to vasoconstriction 
both peripherally and intracranially as well as depression 
of the central vasomotor centers, which accounts for their 
increased risk of peripheral vascular, cardiovascular, and 
cerebrovascular complications.33
The advantage of triptans over other analgesics is the 
fact that triptans not only control pain, but also the non-
headache symptoms of migraine, such as nausea, vomiting, 
photophobia and phonophobia.34,35
Sumatriptan may exert a positive effect in diminishing 
the migraine any time during the headache in some patients. 
In others it works primarily if given early in the headache, but 
not in the aura or prodrome period. Burstein and Jakubowski 
developed an animal model for neurogenic inflammation in 
the mouse, by bathing the dura with an “inflammatory soup”, 
the contents of which approximated the extracellular fluid 
produced at the dura by stimulating the trigeminal ganglion. 
They demonstrated that in animals exposed to inflammatory 
soup, there was sensitization at the trigeminal ganglion cells 
within 20 minutes of exposure. Sumatriptan given before 
20 minutes blocked this response. Sumatriptan given after 
20 minutes was ineffective.36 In a small patient sample, 
Burstein, Collins and Jakubowski showed that two-thirds of 
subjects responded to sumatriptan given early in the head-
ache, but not after 20–30 minutes and one-third responded 
anytime. Ketorolac in their experiment helped prevent 
sensitization at the trigeminal nucleus neurons.37 This helped 
to provide a background rationale for the use of a combina-
tion triptan–NSAID.
Overview of pharmacology 
of sumatriptan–naproxen
Sumatriptan–naproxen has a similar side effect profile to 
sumatriptan.38 Administration recommendation is similar 
to sumatriptan tablets, and despite the fact that it contains 
naproxen there is no recommendation to take it with food.12 
Naproxen should be taken with food, milk or antacids as 
it may cause GI irritation (dyspepsia, bleeding, ulceration, 
perforation).39 Food does not appreciably affect oral bio-
availability of sumatriptan (but prolongs time to peak 
concentration).34,40–43
Sumatriptan–naproxen contraindications, precautions, 
monitoring, pregnancy risk factor and breastfeeding recom-
mendation are otherwise the same as that of its individual 
components.12
Naproxen is contraindicated in: a) Patients with renal insuf-
ficiency, when the creatinine clearance is 30 mL/minute;13 
b) Treatment of the perioperative pain of coronary artery 
bypass graft (CABG) surgery;44 c) Aspirin-sensitive asthma;13 
with note that polymorphism in the leukotriene C(4) synthase 
promoter region (A444C) may contribute to the asthma 
reaction seen with NSAIDs use;45,46 d) Patients with known 
hypersensitivity to aspirin or NSAIDs, or any component of 
the formulation.13
Naproxen should also be used with caution in patients 
with the following problems: a) Known cardiovascular 
disease or cardiovascular risk factors;13 b) Heart failure, 
as it may increase the risk of fluid accumulation and 
edema;13,47 c) Hypertension;13,47 d) On low-dose aspirin for 
antiplatelet therapy, as coadministration of naproxen and 
aspirin interferes with aspirin’s antiplatelet effect; therefore 
naproxen should be administered 2–8 hours or more before 
aspirin or 30–120 minutes after aspirin;13,48,51 e) History of Drug Design, Development and Therapy 2010:4 12
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gastrointestinal (GI) disease, especially peptic ulcer disease 
or GI bleeding;13,52 f) Renal insufficiency, with creatinine 
clearance still 30 mL/minute;13,53 g) Undergoing major 
surgery, as they interfere with platelet aggregation and 
increase the risk of bleeding; therefore, naproxen should be 
withheld for 3–5 half-lives prior to surgery;13,14 h) Asthma 
other than aspirin-sensitive asthma, as they may also have 
aspirin-sensitive asthma;13 i) Hepatic impairment;13,14 
j) On medication with risk of agranulocytosis, such as 
clozapine and carbamazepine, as naproxen may rarely 
cause agranulocytosis;5,46 k) On lithium therapy, as naproxen 
may increase serum lithium levels, with a potential for 
lithium toxicity.13,14
Sumatriptan is contraindicated in patients with:40,54,55 
a) Known hypersensitivity to sumatriptan or any compo-
nent of  the formulation; b) Ischemic heart disease or signs 
or symptoms of ischemic heart disease; c) Cerebrovascular 
disease; d) Peripheral vascular syndromes; e) Uncontrolled 
hypertension; f) Prior use of ergotamine, ergotamine deriva-
tives or another 5-HT1 agonist within the preceding 24-hour 
period; g) Prior (within 2 weeks) or current usage of MAO 
inhibitor; h) Hemiplegic or basilar migraine; i) Severe hepatic 
impairment.
Therefore, patients on sumatriptan–naproxen, because 
of the naproxen component, should be monitored for occult 
blood loss and for their urine output. In addition, periodic 
monitoring of liver function tests, complete blood counts 
(CBC), blood urea nitrogen (BUN) and serum creatinine 
should also be performed.13,14,56
Due to a theoretical concern for increased incidence 
of serotonin syndrome,41,57–59 caution should be exercised 
when using sumatriptan–naproxen, sumatriptan alone, or 
any other triptan in patients with seizure disorders or with 
a lowered seizure threshold, as well as in patients who are 
on a selective serotonin reuptake inhibitor (SSRI) or SNRI. 
This theoretical risk seems however to be unwarranted, since 
the pathophysiology of the serotonin syndrome involves 
activation of 5-HT1A and 5-HT2A receptors, not the receptors 
to which triptans are agonist.60 Several reports also point to 
fact that this does not happen in clinical practice. Even when 
combining a triptan with a SSRI or SNRI, the FDA warning 
is not necessarily warranted.61–63
In terms of hypersensitivity to sumatriptan–naproxen, 
patients should not take this medication if they are allergic 
to either one of its components. For NSAIDs, agents of the 
same class tend to show higher cross-sensitivity. For 
naproxen, other propionic acid based NSAIDs include: 
fenoprofen (Nalfon®), flurbiprofen (Ocufen®), ibuprofen 
(Addaprin; Advil®; Caldolor™; Genpril®; I-Prin; Ibu-200; 
Ibu®; Midol®; Motrin®; NeoProfen®; Proprinal; Ultraprin), 
ketoprofen (Apo-Keto®; Novo-Keto; Nu-Ketoprofen; 
Oruvail®; Rhodis™) and oxaprozin (Daypro®).64 Therefore, 
patients with known sensitivity to any of these medica-
tions should be cautious in their use of sumatriptan–
naproxen. On the other hand, true allergic reaction to 
triptans is extremely rare, and cross-reactivity among 
triptans is unknown. Some triptans, including sumatriptan, 
contain a sulfonamide structure. However cross-reactivity 
between antibiotic sulfonamides and nonantibiotic sulfon-
amides does not occur, or at most has an extremely low 
potential.65–67
The most common side effects of triptans, including 
sumatriptan–naproxen, are chest and neck pressure, tingling, 
paresthesia, flushing, dizziness and sedation.40,54,55 As with 
any of the analgesics, one should always be aware of the 
risk for medication overuse headache with frequent use of 
triptans.68
A major main concern when using triptans in general, 
including sumatriptan and hence sumatriptan–naproxen, is 
the cardiovascular safety.69 A review of clinical data about 
the cardiovascular tolerability and safety of triptans indicates 
that most chest symptoms are nonischemic and nonserious. 
Serious cardiovascular events do occur rarely however, but 
it is in patients with multiple cardiovascular risk factors or 
known cardiovascular disease. Therefore, triptan should be 
considered safe in patients with no or low cardiovascular 
risk.70 As for the naproxen component, it does not seem to 
alter cardiovascular risk, despite the general recommendation 
that NSAIDs and selective COX-2 inhibitors may increase 
cardiovascular complications.71–74
As for pregnancy risk, both naproxen and sumatriptan 
are classified as category C, that is “animal reproduction 
studies have shown an adverse effect on the fetus and there 
are no adequate and well-controlled studies in humans, but 
potential benefits may warrant use of the drug in pregnant 
women despite potential risks”.13,40,54,55 However, there has 
not been an association between naproxen and fetal defects.13 
With sumatriptan, there is lack of adequate studies to assess 
the fetal risk, with some animal studies demonstrating a 
lethal effect on the embryo, while others demonstrating 
no such risk.40,54,55 There is an established pregnancy reg-
istry for sumatriptan (800-336-2176), and many experts in 
embryo-toxicity propagate it to be relatively safe to use sumat-
riptan in pregnant migraine patients, due to the high number of 
observed pregnancies without any severe malformations or 
other teratogenic effect.75,76Drug Design, Development and Therapy 2010:4 13
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Both naproxen and sumatriptan are excreted in breast 
milk,40,41,54–57,59,77 but the American Academy of Pediatrics 
considers them to be breastfeeding “compatible.77”
Overview of pharmacokinetics 
of sumatriptan–naproxen
Though sumatriptan–naproxen shares a similar pharmacologic 
profile with its individual components, its pharmacokinetics 
are different.
Maximal concentration (Cmax) for sumatriptan following 
administration of sumatriptan–naproxen occurs at approxi-
mately 1 hour (median, range 0.3 to 4.0 hours). Cmax for 
naproxen following administration of sumatriptan–naproxen 
occurs at approximately 5 hours (median, range 0.3 to 
12 hours). The mean Cmax for sumatriptan when given as 
sumatriptan–naproxen is similar to that of sumatriptan when 
given as a 100 mg tablet alone.78 By contrast, naproxen 
administered alone reaches peak serum concentration in 1 to 4 
hours.13,21,79 This is approximately 36% lower than with the com-
bination tablet; thus, the combination tablet seems to delay the 
time to maximum concentration of the naproxen.78
In the combination tablet, the sumatriptan half-life is 
approximately 2 hours (15% to 43% CV) and the naproxen 
half-life is approximately 19 hours (13% to 15% CV). The 
median sumatriptan time to maximum concentration (Tmax) is 
only slightly different (1 hour for sumatriptan–naproxen and 
1.5 hours for sumatriptan 100 mg tablets), and the Tmax occurs 
approximately 4 hours later from sumatriptan–naproxen than 
from the 550 mg naproxen sodium tablets. The areas under 
the curve however for sumatriptan and for naproxen are 
similar for sumatriptan–naproxen compared to the individual 
tablets of its component.78
Naproxen is almost completely albumin bound in the 
serum with a volume of distribution of 0.16 L/kg. For the acute 
treatment of pain, it has a one hour onset of action. However, 
the onset of action of its anti-inflammatory effect is around 
2 weeks, with a peak of action at 2–4 weeks. Its analgesic 
effect lasts up to 7 hours and its anti-inflammatory effect up to 
12 hours.13,21,79 Sumatriptan’s volume of distribution is 2.4 L/kg 
and it is partly protein bound (14% to 21%).34,40–43,54–57,80–104
Naproxen is metabolized in the liver and is a minor sub-
strate of the CYP1A2 and CYP2C9 enzyme. Its metabolites 
are primarily eliminated in the urine (95%), with a half-
life elimination of up to12 hours. Only a minor fraction is 
excreted in feces.13,14 On the other hand, 40% of the total dose of 
oral sumatriptan is excreted in feces and the remainder in urine. 
Urinary elimination consists of  both the indole acetic metabolite 
as well as the unchanged drug.34,40–43,54–57,81,82,87,91–93,104–108
It is recommended that sumatriptan, sumatriptan–naproxen 
and all other triptans be administered at the onset of head-
ache, or as soon as possible in the migraine attack, but not 
during the aura symptoms that occur at the beginning of an 
attack. If the headache persists, then a second dose may be 
administered at 2 hours, with a maximum of 2 doses within 
a 24-hour period. This is true for all formulations and all 
dosages. It is not recommended to combine different trip-
tans.34,36,40,41,54–57,81,84,85,89,107,109–111
There are no specific dose adjustments required in the 
elderly.13,54,55,91 However, the free plasma level of naproxen is 
higher in geriatrics than in younger adults, and the elderly are at 
increased risk for adverse effects even at low doses. Therefore 
one might therefore need to start with lower dosages.13,14
Sumatriptan–naproxen 
efficacy studies
Both concomitant administration of sumatriptan and 
naproxen and sumatriptan–naproxen fixed combination tablet 
(Treximet®) have been shown to have superior efficacy to 
either one of the two medicines used alone, with a synergistic 
effect being noted.112 Summary of the two seminal studies 
that led to the approval of sumatriptan–naproxen by the FDA 
is shown (Table 1).38
Similar to sumatriptan, sumatriptan–naproxen addresses 
both the headache and the nonheadache symptoms of 
migraine, namely photophobia, phonophobia and nausea.38
Sumatriptan–naproxen shows consistency of response 
in other study designs too. In two cross over studies, 
sumatriptan–naproxen combination shows greater response 
than placebo in terms of pain freedom 2-hour postdose (52% 
versus 25% in study 1 and 50% versus 20% in study 2), 
in sustained pain freedom at 24 hours (37% versus 17% in 
study 1 and 34% versus 12% in study 2), and in migraine 
freedom at 2 hours and 4 hours postdose (no pain, nau-
sea, vomiting, photophobia, phonophobia, and no use of 
rescue medications). Adverse events were 9% (versus 7% 
in the placebo group) in study 1 and 13% (versus 9% in 
the placebo group) in study 2.113 More importantly, even 
in migraineurs who do not respond to sumatriptan mono-
therapy, sumatriptan–naproxen demonstrates greater efficacy 
than placebo in aborting migraine attacks, both in terms 
of pain as well as photophobia and phonophobia. In two 
studies by Mathew and colleagues a 2 hour pain free rate 
with sumatriptan–naproxen was 40% and 44% versus 17% 
and 14% for placebo, and sustained pain freedom rates 
at 2 to 24 hours with sumatriptan–naproxen were 26% and 
37% versus with 8% and 8% for placebo.114Drug Design, Development and Therapy 2010:4 14
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Sumatriptan–naproxen is not only effective against the 
traditional symptoms of migraine (pain, nausea, vomiting, 
photophobia, phonophobia), but also the nontraditional 
migraine symptoms (neck pain/discomfort, sinus pain/
pressure). In 2 identical, randomized, double-blind, placebo-
controlled trials that enrolled 576 and 535 migraineurs 
respectively, with similar incidence of different migraine 
symptoms between the treated and the placebo group, after 
early treatment the nontraditional symptoms occurrence 
2 hours and 4 hours post-treatment were significantly lower 
as compared to placebo (Table 2).115
Sumatriptan–naproxen also showed superior efficacy and 
tolerability vs placebo in the treatment of menstrual migraine 
and dysmenorrhea in 2 replicate studies. This effect was 
seen for 2-hour pain response, 2 hour to 48 hours sustained 
pain response, use of rescue medications and in nonmigraine 
menstrual symptoms (bloating, tiredness, irritability, overall 
nonmigraine pain intensity), except for menstrual pain.116
Despite the advantage of sumatriptan–naproxen, there is a 
relative lack of data comparing it directly to its components. 
The improved efficacy in clinical trials over sumatriptan is in 
the range of only 5% to 10%. In addition, the efficacy of sumat-
riptan in the sumatriptan–naproxen studies is lower than was 
previously reported.117 One must therefore weigh this advantage 
against the significantly higher price of sumatriptan–naproxen 
compared to its components, where sumatriptan–naproxen 
costs around $22.00 per dose versus $6.60 per dose for 
generic sumatriptan 100 mg and generic naproxen 500 mg.118
Patient focused perspectives such 
as quality of life, patient satisfaction/
acceptability, adherence and uptake
A recent study identified 5 factors that predict patient adher-
ence to triptan therapy.119 In decreasing order of importance, 
these include: a) Confidence in the triptan’s ability to abort the 
migraine attack; b) The perceived importance of the triptan in the 
treatment of the migraine attack; c) Satisfaction with the triptan; 
d) Speed of onset of triptan analgesic effect; e) Time to disability 
resolution and patient’s return to normal activities. A negative 
predictive factor was the occurrence of side effects. Migraine 
severity was not a predictive factor of adherence to therapy.
Sumatriptan–naproxen, with its consistent efficacy 
response and favorable side effect profile113 increases the 
likelihood of adherence by patients. Over a 12-month period, 
it demonstrated consistent efficacy with low recurrence rates, 
Table 1 Percentage of patients with 2-hour pain relief and sustained pain relief following treatment*38
Sumatriptan–naproxen Sumatriptan 85 mg Naproxen sodium 500 mg Placebo
2-hour pain relief
















Sustained pain relief (2 to 24 hours)
















*P values provided only for prespecified comparisons.
†P  0.05 versus placebo and sumatriptan.
‡P  0.01 versus placebo, sumatriptan, and naproxen sodium.
Table 2 Occurrence of nontraditional migraine symptoms 2-hour and 4-hour following treatment115
Study 1 Study 2
Sumatriptan–naproxen Placebo Sumatriptan–naproxen Placebo
Neck pain/discomfort 2-hour postdose 35% 44% 28% 54%
Neck pain/discomfort 4-hour postdose 19% 46% 19% 46%
Sinus pressure/pain 2-hour postdose 19% 35% 23% 38%
Sinus pressure/pain 4-hour postdose 10% 30% 15% 32%
All results significant at 0.001 or less.Drug Design, Development and Therapy 2010:4 15
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and tolerability with low side effect rates and improved 
quality of life scores, again resulting in improved patient 
satisfaction and hence improved patient compliance.120
Conclusions and place in therapy
Sumatriptan–naproxen sodium fixed combination tablet 
(Treximet®) theoretically will abort migraine in its initial 
stages at the trigeminal ganglion and will prevent the slow 
central sensitization.
The combination is modestly superior to sumatriptan or 
naproxen alone, as shown in the 2 seminal studies;38 however 
the 50% to 55% 2-hour pain relief and 14% to 16% 2 hour 
pain freedom for sumatriptan are lower than the efficacy 
reported for sumatriptan in the triptan meta-analysis by 
Ferrari and colleagues.117
Sumatriptan–naproxen may restore responsiveness in 
subjects that have become tachyphylactic to triptans, and 
has a favorable side-effect profile, making it an effective 
and well-tolerated migraine abortive treatment, but it is far 
from being the gold standard treatment. Research to develop 
additional medication is still needed.
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